Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Evolus Expands Management Team with Appointment of Michael Mazen Jafar as Chief Marketing Officer


Posted on: 18 Jun 18

Mr. Jafar Joins Evolus from Allergan as the Company Expands its Commercial Infrastructure

IRVINE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced the expansion of its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics.

At Allergan Mr. Jafar led the commercial launch of Juvederm Voluma®, which has been recognized as not only one of the largest launches in the medical aesthetics category, but also the most successful, as measured by year one sales. He also led product development and marketing initiatives for the Botox® Cosmetic, Juvederm®, Kybella®, Latisse®, and Natrelle® franchises at Allergan. His most recent role at Allergan was to lead the market assessment and subsequent integration of the CoolSculpting® franchise acquired from Zeltiq.

Mr. Jafar has more than a decade of product development, upstream and downstream marketing, and commercial assessment experience and has launched several direct-to-consumer campaigns and market transformational initiatives.

David Moatazedi, President and Chief Executive Officer of Evolus, stated, “I am pleased to announce another exceptional addition to our management team as we continue to evaluate our value proposition and expand our world class commercial infrastructure ahead of the anticipated launch of our lead product candidate, DWP-450. I am confident that Mike will have an immediate impact on our organization and bring a fresh perspective to our team as we further develop and execute our commercial strategy.”

Michael Jafar, Chief Marketing Officer, said, “Evolus represents an unparalleled opportunity to build a premier aesthetics-only franchise while developing a dynamic and customer centric platform company to best penetrate the large and growing cash-pay aesthetics market.  I am excited to leverage my diverse skill set, market knowledge, and broad experience in bringing novel products to market to drive the commercial success of DWP-450 upon regulatory approval.”

Prior to his move into medical aesthetics, Mr. Jafar held a number of roles of increasing responsibility in Allergan’s ophthalmic division. Mr. Jafar holds an MBA from the University of Southern California and a BA with an emphasis on international finance and supply chain management from the University of San Diego.

About Evolus, Inc.

Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures.  Evolus’ lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that is being evaluated for the treatment of moderate to severe glabellar lines.

Forward-Looking Statements

Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "planned," "expect," "believes," "strategy," "opportunity," "anticipates," "outlook," "designed," and similar words.  While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Evolus’ periodic filings with the Securities and Exchange Commission, including factors described in the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2017 and its Quarterly Report on Form 10-Q for the Quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on March 29, 2018 and May 10, 2018, respectively, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Evolus undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

Evolus Contacts:

Investor Contact:
Brian Johnston, The Ruth Group
Tel: +1 646-536-7028
Email: IR@Evolus.com

Media:
Kirsten Thomas, The Ruth Group
Tel: +1-508-280-6592
Email: kthomas@theruthgroup.com

CoolSculpting® is a registered trademark of Zeltiq Aesthetics, Inc.
Juvederm Voluma®, Botox®, Latisse®, and Natrelle® are registered trademarks of Allergan, Inc.
Kybella® is a registered trademark of Kythera Biopharmaceuticals, Inc.

GlobeNewswire
globenewswire.com

Last updated on: 18/06/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.